-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CxjannWnHaG2Mkrnz66LR0bEvGkJD1PFz+9NLYwOPqyJNbkMEChkr6L2F8gebHOR lohxYnlQd2pwOjPPt+PK0Q== 0000062391-99-000011.txt : 19991224 0000062391-99-000011.hdr.sgml : 19991224 ACCESSION NUMBER: 0000062391-99-000011 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19991223 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CELL GENESYS INC CENTRAL INDEX KEY: 0000865231 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943061375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-43085 FILM NUMBER: 99779473 BUSINESS ADDRESS: STREET 1: 342 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6504254400 MAIL ADDRESS: STREET 1: 342 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HOECHST MARION ROUSSEL INC CENTRAL INDEX KEY: 0000062391 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 440565557 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 BUSINESS PHONE: 8169665000 MAIL ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 FORMER COMPANY: FORMER CONFORMED NAME: MARION MERRELL DOW INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: MARION LABORATORIES INC DATE OF NAME CHANGE: 19891218 SC 13G/A 1 AMENDMENT NO. 1 TO SCHEDULE 13G =========================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 CELL GENESYS, INC. ---------------------------- (Name of Issuer) COMMON STOCK, $.001 PAR VALUE - --------------------------------------------------------------------------- (Title of Class of Securities) 150921 10 4 ----------------- (CUSIP Number) December 15, 1999 ------------------------------------------------------- (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ x ] Rule 13d-1(c) [ ] Rule 13d-1(d) =========================================================================== Page 1 of 9 Exhibit Index is located at page 8 2 CUSIP No. 150921 10 4 - --------------------------------------------------------------------------- 1) Name of Reporting Person and its Aventis Pharmaceuticals Inc. I.R.S. Identification Number 44-0565557 - --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ ] - --------------------------------------------------------------------------- 3) SEC Use Only - --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - --------------------------------------------------------------------------- 5) Sole Voting Power 2,750,000* Number of ____________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 2,750,000* Person With ____________________________________________________________ 8) Shared Dispositive Power 0 - --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 2,750,000* by Each Reporting Person - --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares - --------------------------------------------------------------------------- 11) Percent of Class Represented 8.30% by Amount in Row (9) - --------------------------------------------------------------------------- 12) Type of Reporting Person CO - --------------------------------------------------------------------------- * Includes up to 750,000 shares that may be purchased for $13.00 per share upon the exercise of a Common Stock Purchase Warrant during the period beginning November 27, 1995, and ending October 9, 2000. 3 CUSIP No. 150921 10 4 13G - --------------------------------------------------------------------------- 1) Name of Reporting Person and its HMR Pharma, Inc. I.R.S. Identification Number 43-1769328 - --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ ] - --------------------------------------------------------------------------- 3) SEC Use Only - --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - --------------------------------------------------------------------------- 5) Sole Voting Power 2,750,000* Number of ____________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 2,750,000* Person With ____________________________________________________________ 8) Shared Dispositive Power 0 - --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 2,750,000* by Each Reporting Person - --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares - --------------------------------------------------------------------------- 11) Percent of Class Represented 8.30% by Amount in Row (9) - --------------------------------------------------------------------------- 12) Type of Reporting Person CO - --------------------------------------------------------------------------- * Includes up to 750,000 shares that may be purchased for $13.00 per share upon the exercise of a Common Stock Purchase Warrant during the period beginning November 27, 1995, and ending October 9, 2000. 4 CUSIP No. 150921 10 4 13G This Amendment No. 1 to the Statement on Schedule 13G with respect to the Common Stock of Cell Genesys, Inc. (the "Issuer"), is filed jointly by Aventis Pharmaceuticals Inc., a Delaware corporation ("Aventis"), and HMR Pharma, Inc., a Delaware corporation ("Pharma"), to reflect the change of name of Hoechst Marion Roussel, Inc., to Aventis Pharmaceuticals Inc. The following items of the Statement on Schedule 13G are hereby amended to read as follows: ITEM 2(a). NAME OF PERSON FILING: - ---------- ---------------------- Aventis Pharmaceuticals Inc. HMR Pharma, Inc. ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: - ---------- ------------------------------------------------------------ Aventis Pharmaceuticals Inc. 10236 Marion Park Drive Kansas City, Missouri 64137-1405 HMR Pharma, Inc. 10236 Marion Park Drive Kansas City, Missouri 64137-1405 ITEM 2(c). CITIZENSHIP: - ---------- ------------ Delaware As To Both Aventis Pharmaceuticals Inc. And HMR Pharma, Inc. 5 CUSIP No. 150921 10 4 13G ITEM 4. OWNERSHIP - ------- --------- (a): AMOUNT BENEFICIALLY OWNED: As Of 10/29/99 2,000,000 Shares Of Common Stock And A Warrant To Purchase Up To 750,000 Warrant Shares At $13.00 Per Share During The Period Beginning 11/27/1995 And Ending 10/09/2000. (b): PERCENT OF CLASS: 8.30% (c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS: (i) Sole power to vote or to direct the vote: 2,750,000 (ii) Shared power to vote or to direct the vote: 0 (iii)Sole power to dispose or to direct the 2,750,000 disposition of: (iv) Shared power to dispose or to direct the 0 disposition of: 6 CUSIP No. 150921 10 4 13G SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. AVENTIS PHARMACEUTICALS INC. Date: December 22, 1999 By: /s/ Rebecca R. Tilden --------------------------------- Rebecca R. Tilden Vice President and Secretary 7 CUSIP No. 150921 10 4 13G SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. HMR PHARMA, INC. Date: December 22, 1999 By: /s/ Rebecca R. Tilden ----------------------------- Rebecca R. Tilden Vice President and Assistant Secretary 8 CUSIP No. 150921 10 4 13G EXHIBIT INDEX Exhibit No. Description Page No. - ----------- ------------ --------- 99.A Agreement to File Jointly dated December 9 22, 1999, by and between Aventis Pharmaceuticals Inc. and HMR Pharma, Inc. 9 CUSIP No. 150921 10 4 13G EXHIBIT 99.A AGREEMENT TO FILE JOINTLY We, the undersigned, hereby express our agreement that the attached Schedule 13G is filed on behalf of each of us. AVENTIS PHARMACEUTICALS INC. Date: December 22, 1999 By: /s/ Rebecca R. Tilden ------------------------------- Rebecca R. Tilden Vice President and Secretary HMR PHARMA, INC. Date: December 22, 1999 By: /s/ Rebecca R. Tilden -------------------------- Rebecca R. Tilden Vice President and Assistant Secretary -----END PRIVACY-ENHANCED MESSAGE-----